Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020).

Renaud Descourt, Alice Mogenet, Maelys Consigny, Marie Bernardi, Romain Corre, Olivier Bylicki, Jean-Bernard Auliac, Alain Vergnenègre, Charles Ricordel, Julian Pinsolle, Marie Wislez, Maud Pedrono, Rémi Veillon, Lionel Falchero, Florian Guisier, Pierre-Alexandre Hauss, Acya Bizieux-Thaminy, Stéphane Hominal, Anne Madroszyk, Hubert Curcio, Roland Schott, Eric Huchot, Benjamin Besse, Chrystèle Locher, Jacques Le Treut, Marie-Capucine Willemin, Géraldine François, Arnaud Uguen, Maurice Pérol, Christos Chouaïd, Laurent Greillier, Chantal Decroisette

DOI: 10.1016/j.annonc.2026.10.108

На странице источника доступны аннотация, полный текст или сведения о том, где его прочитать.